10 studies found for:
MEDI-522
Create an RSS feed from your search for:
Download the search results for:| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Terminated |
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
|
||||
| 2 | Completed |
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
|
||||
| 3 | Completed |
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
|
||||
| 4 | Completed |
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
|
||||
| 5 | Completed |
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
|
||||
| 6 | Completed |
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
|
||||
| 7 | Completed |
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
|
||||
| 8 | Completed |
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
|
||||
| 9 | Completed |
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
|
||||
| 10 | Completed |
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
|
† Indicates status has not been verified in more than two years